Bedminster, N.J.-based Jubilant Discovery Services is working with Johnson & Johnson’s Janssen division for an initial three-year period. The alliance will focus on multiple drug targets in neuroscience.
Janssen will transfer certain ongoing efforts on selected drug discovery targets to Jubilant, while Jubilant will contribute research services and deliver pre-clinical candidates to Janssen for possible further development and commercialization.
Jubilant may be eligible for milestones and royalties should Janssen successfully develop and commercialize drug candidates covered by the alliance, Jubilant noted.
The collaboration will draw on Jubilant’s global research network, including a new research facility in the U.S. focused on neuroscience, as well as the company’s India-based research centers.